Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer

• Main Authors: Shao-Lun Lu, Feng-Ming Hsu, Kuan-Yu Chen, Chao-Chi Ho, James Chih-Hsin Yang, Jason Chia-Hsien Cheng
• Format: Article
• Language: English
• Published: Karger Publishers 2016-08-01
• Series: Case Reports in Oncology
• Subjects: Maintenance pemetrexed; Oligoprogression; Stereotactic ablative radiotherapy
• Online Access: http://www.karger.com/Article/FullText/448804

Maintenance pemetrexed offers survival benefit with well-tolerated toxicities for advanced non-squamous non-small cell lung cancer (NSCLC). We present 3 consecutively enrolled patients with advanced non-squamous NSCLC, receiving stereotactic ablative radiotherapy (SABR) for oligoprogressive disease during maintenance pemetrexed. All of them had sustained local control of thoracic oligoprogression after the SABR, while maintenance pemetrexed were kept for additionally long progression-free interval. SABR targeting oligoprogression with continued pemetrexed is an effective and safe approach to extend exposure of maintenance pemetrexed, thus maximizing the benefit from it.